Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-25T07:42:48.598Z Has data issue: false hasContentIssue false
  • English
  • Français

Remission of Multiple Sclerosis Post-Liver Transplantation

Published online by Cambridge University Press:  02 December 2014

Eric M. Yoshida ,
Virginia A. Devonshire  and
Alister J.E. Prout
Eric M. Yoshida
Affiliation:
Divisions of Neurology and Gastroenterology, University of British Columbia, Vancouver, BC, Canada
Virginia A. Devonshire
Affiliation:
Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Alister J.E. Prout
Affiliation:
Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The effect of liver transplantation on pre-existing multiple sclerosis (MS) has never been reported. We report the three year post-transplant neurological outcome of a patient with MS.

Case report:

A Caucasian woman with MS received an urgent liver transplant for fulminant liver failure at the age of 59. Her Extended Disability Scale Score (EDSS) pretransplant was 5.0 and clinically she had cerebellar and brainstem dysfunction. Post-transplant immunosuppression consisted of tacrolimus, mycophenolate mofetil and tapering corticosteroids that were discontinued after 1.5 years. Post-transplant her EDSS decreased to 2.0 and after three years she is clinically asymptomatic with only very mild dysarthria on neurologic examination. Long-term maintenance immunosuppression consists of low dose tacrolimus.

Conclusion:

Combination immunosuppression with tacrolimus may have a beneficial effect on MS although an effect of donor allograft itself can not be excluded.

Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 31 , Issue 4 , November 2004 , pp. 539 - 541
Copyright
Copyright © The Canadian Journal of Neurological 2004

References

1. Milligan, NM, Newcombe, R, Compston, DA. A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511–516.CrossRefGoogle ScholarPubMed
2. Zivadinov, R, Rudick, RA, de Masi, R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239–1247.Google Scholar
3. Fassas, A, Passweg, JR, Anagnostopoulos, A, et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002; 249: 1088–1097.Google Scholar
4. Starzl, TE, Demetris, AJ, Trucco, M, et al. Systemic chimerism in human female recipients of male livers. Lancet 1992; 340: 867–876.Google Scholar
5. Ahrens, N, Salama, A, Haas, J. Mycophenolate-mofetil in the treatment of refractory MS. J Neurol 2001;248(8):713–714.CrossRefGoogle Scholar
6. Mueller, AR, Platz, KP, Schattenfroh, N, et al. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. Transpl Int 1994;7 (Suppl 1):S37–S42.Google Scholar
7. Bartynski, WS, Zeigler, Z, Spearman, MP, et al. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol 2001;(10):1901–1914.Google Scholar
8. McMichael, J, Lieberman, R, McCauley, J, et al. Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. Ther Drug Monit 1996;18(4):435–437.CrossRefGoogle ScholarPubMed
9. Collins, RH Jr, Anastasi, J, Terstappen, LW, et al. Brief report: donor-derived long-term multilineage hematopoiesis in a liver-transplant recipient. N Engl J Med 1993; 328: 762–765.Google Scholar
10. Yoshida, EM, Rasmussen, SL, Steinbrecher, UP, et al. Fulminant liver failure during interferon beta treatment of MS. Neurology 2001 ;56(10):1416. Erratum in: Neurology 2001; 57: 2153.Google Scholar
11. Thyagarajan, GK, Cobanoglu, A, Johnston, W. FK 506-induced fulminant leukoencephalopathy after single-lung transplantation. Ann Thorac Surg 1997;64(5):1461–1464.Google Scholar
12. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990;27(6):591–605.Google Scholar
13. Hartung, HP, Gonsette, R, Konig, N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled double-blind, randomised muticentre trial. Lancet 2002; 360: 2018–2025.Google Scholar
14. Lemster, B, Huang, LL, Irish, W, et al. Influence of FK 506 on circulating CD4+ T cells expressing CD25 and CD45RAantigens in 19 patients with chronic progressive MS participating in an open label drug safety trial. Autoimmunity 1994;19(2):89–93.Google Scholar